Cite
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.
MLA
Ohnuma, Hiroyuki, et al. “Docetaxel, Cisplatin and S-1 (DCS) Combination Chemotherapy for Gastric Cancer Patients with Peritoneal Metastasis: A Retrospective Study.” Cancer Chemotherapy and Pharmacology, vol. 81, no. 3, Mar. 2018, pp. 539–48. EBSCOhost, https://doi.org/10.1007/s00280-018-3523-x.
APA
Ohnuma, H., Sato, Y., Hirakawa, M., Kikuchi, S., Miyanishi, K., Sagawa, T., Takahashi, Y., Nobuoka, T., Okamoto, K., Miyamoto, H., Takemasa, I., Takayama, T., & Kato, J. (2018). Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemotherapy and Pharmacology, 81(3), 539–548. https://doi.org/10.1007/s00280-018-3523-x
Chicago
Ohnuma, Hiroyuki, Yasushi Sato, Masahiro Hirakawa, Shohei Kikuchi, Koji Miyanishi, Tamotsu Sagawa, Yasuo Takahashi, et al. 2018. “Docetaxel, Cisplatin and S-1 (DCS) Combination Chemotherapy for Gastric Cancer Patients with Peritoneal Metastasis: A Retrospective Study.” Cancer Chemotherapy and Pharmacology 81 (3): 539–48. doi:10.1007/s00280-018-3523-x.